<table>
<thead>
<tr>
<th>Title</th>
<th>Expression of alpha smooth muscle actin in living donor liver transplant recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Hirabaru, Masataka; Mochizuki, Kyoko; Takatsuki, Mitsuhisa; Soyama, Akihiko; Kosaka, Taiichiro; Kuroki, Tamotsu; Shimokawa, Isao; Eguchi, Susumu</td>
</tr>
<tr>
<td>Citation</td>
<td>World Journal of Gastroenterology, 20(22), pp.7067-7074; 2014</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2014-06-14</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10069/34553">http://hdl.handle.net/10069/34553</a></td>
</tr>
</tbody>
</table>

©1995-2014 Baishideng Publishing Group Inc. All rights reserved. Articles published by this open-access journal are distributed under the terms of the Creative Commons Attribution-Noncommercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

NAOSITE: Nagasaki University's Academic Output SITE

NAOSITE Nagasaki university's Academic Output SITE 長崎大学学術研究成果ポジトリ
Expression of alpha smooth muscle actin in living donor liver transplant recipients

Masataka Hirabaru, Kyoko Mochizuki, Mitsuhisa Takatsuki, Akihiko Soyama, Taiichiro Kosaka, Tamotsu Kuroki, Isao Shimokawa, Susumu Eguchi

Masataka Hirabaru, Kyoko Mochizuki, Mitsuhisa Takatsuki, Akihiko Soyama, Taiichiro Kosaka, Tamotsu Kuroki, Susumu Eguchi, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan
Isao Shimokawa, Department of Investigative Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan

Author contributions: Hirabaru M and Eguchi S contributed equally to this work; Hirabaru M, Mochizuki K and Eguchi S designed the study; Hirabaru M, Eguchi S, Mochizuki K, Takatsuki M, Soyama A, Kosaka T, Kuroki T, Shimokawa I and Eguchi S performed the study and analyzed the data; and Hirabaru M and Eguchi S wrote the manuscript.

Correspondence to: Susumu Eguchi, MD, PhD, Department of Surgery, Nagasaki University Graduate School of Biomedical sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. sueguchi@nagasaki-u.ac.jp
Telephone: +81-95-8197316 Fax: +81-95-8197319
Received: October 22, 2013 Revised: December 31, 2013 Accepted: February 26, 2014 Published online: June 14, 2014

Abstract

Recently, there have been reports from liver biopsies that showed the progression of liver fibrosis in liver transplant patients after the cessation of immunosuppression. Herein, we focused on activated hepatic stellate cells expressing alpha smooth muscle actin (α-SMA) to understand the correlation between immunosuppressant medication and liver fibrosis. The study enrolled two pediatric patients who underwent living donor liver transplantation and ceased immunosuppressant therapy. The number of α-SMA-positive cells in the specimens obtained by liver biopsy from these two patients showed a three-fold increase compared with the number from four transplanted pediatric patients who were continuing immunosuppressant therapy. In addition, the α-SMA-positive area evaluated using the WinRooF image processing software program continued to increase over time in three adult transplanted patients with liver fibrosis, and the α-SMA-positive area was increasing even during the pre-fibrotic stage in these adult cases, according to a retrospective review. Therefore, α-SMA could be a useful marker for the detection of early stage fibrosis.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Living donor liver transplantation; Liver fibrosis; Immunosuppressant therapy; Alpha smooth muscle actin; Hepatic stellate cells

Core tip: The primary finding presented in this case report is that there is that the cessation of immunosuppressant therapy may promote liver fibrosis in patients after liver transplantation, even though normal liver function is maintained. In addition, the alpha smooth muscle actin (α-SMA)-positive area increased during the pre-fibrotic stage. Therefore, α-SMA may serve as a useful marker to detect early stage fibrosis.


INTRODUCTION

Liver transplantation is an established treatment for hepatic failure. Recent developments in surgical techniques, anesthestia and perioperative management have contributed to a decrease in early mortality after liver transplantation. However, the mortality in patients with chronic hepatic failure has remained unchanged11. Some of the causes of
the poor prognosis for these patients include renal disor-
ders, vascular disorders, malignant tumors, and the use of
immunosuppressant medication[8-4]. Therefore, a reduction
in such medication may reduce the mortality rate[8].

Despite many reports describing patients who have
acquired immune tolerance[8-7], the characteristics of pa-
tients with immune tolerance are still unknown[9]. Clinical
immune tolerance refers to the state of maintaining nor-
mal organ graft function even after the cessation of im-
munosuppressant medication[9,10]. In practice, the cessa-
tion of immunosuppressant medication varies depending
on each patient’s condition and must be individualized;
although some patients have a favorable postoperative
course and can successfully achieve a reduction of immu-
nosuppressant medication, other patients have no choice
but to stop the treatment, such as in the case of infec-
tion with the Epstein-Barr virus (EBV). The probability of
adult patients acquiring immune tolerance has been re-
ported to be 8%-33%[11,18], and this rate has been sug-
gested to be much higher in pediatric patients[6,19,20].

However, liver transplant recipients with no abnor-
malities in hepatic function after the cessation of immu-
ynosuppressant medication have recently been reported
to develop hepatic fibrosis, with the hepatic fibrosis
improving after resumption of the medication[21]. There-
fore, there is a need to understand the mechanism(s) of
hepatic fibrosis induced by withdrawal of immunosup-
pression. We have herein focused on hepatic stellate
cells (HSCs), which may be involved in hepatic fibrosis.
HSCs constitute a large portion of the hepatic intersti-
tium, representing 5%-8% of the total number of liver
cells[22]. In the healthy liver, HSCs are quiescent, but can
be activated by factors, including TGFβ1 and IFNγ, that
are released by Kupffer cells (KC) and T cells after injury
or stimulation[22,23]. The appearance of alpha smooth
muscle actin (α-SMA) in the activated HSCs can be de-
tected using α-SMA immunostaining[24]. Activated HSCs
undergo apoptosis at sites of acute inflammation but
induce sinusoidal sclerosis, leading to the development of
sinusoidal portal hypertension at sites of chronic inflam-

### Immunohistochemistry

Four-micrometer-thick sections, cut from formalin-fixed,
paraffin-embedded tissues, were immunohistochemically
stained for SMA, CD68, and CD79α. The following pri-
mary antibodies and a staining kit [MAX-PO (MULTI),
Nichirei Corporation, Tokyo, Japan] containing peroxi-
dase-labeled secondary antibodies were used: anti-alpha-
SMA (Nichirei; Code 412021), anti-CD68 (Dako, Tokyo,
Japan; Code M0814), and anti-CD79α (Dako; Code
N162830). The immunostaining was performed accord-
ing to the manufacturer’s instructions.

### Histology score-based semiquantitative analysis

A semiquantitative analysis was performed by light mi-
croscopy at ×100 magnification, and the number of
positively immunostained cells was calculated in five arbi-
trarily selected fields of view.

### Computer-assisted semiquantitative analysis

The tissues in the α-SMA-stained area were subjected to
objective semiquantitative analysis using the WinROOF
image processing software program (MITANI Corpora-
tion, Tokyo, Japan). The ratio of the positive area in the
specimen to the total area was calculated.

### Immunohistochemistry in pediatric patients with
immune tolerance

The number of cells in five randomly selected fields of
view (Table 1) that were α-SMA-positive was 250.5 ±
102.8 (mean ± SD) in the two pediatric patients with
tolerance, whereas the count was 69.6 ± 67.7 in the
four pediatric cases without tolerance. The numbers of

---

**CASE REPORT**

**Patients**

A total of 163 patients underwent LDLT in our depart-
ment from August 1997 to May 2012. Among them, 12
were pediatric patients who were less than 18 years of
age, and 2 of these pediatric patients had ceased immu-
ynosuppressant medication for a long period. One patient
was an 18-year-old male who underwent LDLT for bili-
ary atresia (BA) at 5-years of age. In this case, immuno-
pression (IS) was stopped according to the weaning
protocol because of his good condition 68 mo after the
LDLT. Another patient was an 11-year-old female who
underwent LDLT for BA at 11-mo of age. Her IS was
stopped non-electively because of EBV infection 3 mo
after the LDLT. A total of eight liver biopsies were per-
fomed in these two patients. As a control, this study also
included four pediatric patients who did not have hepatic
function abnormalities or fibrosis and continued their
immunosuppressant medication (no-tolerance cases).

To examine whether the findings in these pediatric cases
were also relevant to adult patients with fibrosis, three
randomly selected patients with liver fibrosis not due to
hepatitis C were evaluated.

Specimens were collected by ultrasound-guided core
needle biopsy. Each specimen was stained with hematoxy-
in eosin, and the severity of fibrosis was determined us-
ing Ishak’s modified staging system[26]. The evaluation of
each specimen was conducted blindly by two pathologists.

---

**Patients**

A total of 163 patients underwent LDLT in our depart-
ment from August 1997 to May 2012. Among them, 12
were pediatric patients who were less than 18 years of
age, and 2 of these pediatric patients had ceased immu-
ynosuppressant medication for a long period. One patient
was an 18-year-old male who underwent LDLT for bili-
ary atresia (BA) at 5-years of age. In this case, immuno-
pression (IS) was stopped according to the weaning
protocol because of his good condition 68 mo after the
LDLT. Another patient was an 11-year-old female who
underwent LDLT for BA at 11-mo of age. Her IS was
stopped non-electively because of EBV infection 3 mo
after the LDLT. A total of eight liver biopsies were per-
fomed in these two patients. As a control, this study also
included four pediatric patients who did not have hepatic
function abnormalities or fibrosis and continued their
immunosuppressant medication (no-tolerance cases).

To examine whether the findings in these pediatric cases
were also relevant to adult patients with fibrosis, three
randomly selected patients with liver fibrosis not due to
hepatitis C were evaluated.

Specimens were collected by ultrasound-guided core
needle biopsy. Each specimen was stained with hematoxy-
in eosin, and the severity of fibrosis was determined us-
ing Ishak’s modified staging system[26]. The evaluation of
each specimen was conducted blindly by two pathologists.
CD68/CD79α-positive cells in the cases with and without tolerance were 398.2 ± 121.6/14.8 ± 8.7 and 413.5 ± 164.2/10.3 ± 4.6, respectively.

In addition, the number of α-SMA-positive cells was 227.5 ± 99.0 in the tolerant patients with F0 stage fibrosis, which was higher than that in the patients without tolerance. The α-SMA-positive area ratio was also calculated using the WinROOF software program. The α-SMA-positive area ratio in the patients without tolerance with any fibrotic stage was 2.3% ± 0.46%; it was 2.2% ± 0.47% in cases with fibrotic stage F0 and 0.75% ± 0.53% in the no-tolerance patients (all patients with fibrotic stage F0).

Accordingly, even among patients with no findings of fibrosis, the α-SMA area ratio was higher in patients with tolerance than in those without tolerance.

**Table 1** Characteristics of patients in tolerance cases and no tolerance cases

<table>
<thead>
<tr>
<th>Tolerance cases</th>
<th>Pediatr Case</th>
<th>Age at LDLT</th>
<th>Sex</th>
<th>Original disease</th>
<th>Duration of biopsy after cessation of IS (F Stage)</th>
<th>Fibrosis (F Stage)</th>
<th>Positive area of α-SMA (%)</th>
<th>Number of positive cells/5 fields</th>
<th>CD68</th>
<th>CD79α</th>
</tr>
</thead>
<tbody>
<tr>
<td>No tolerance cases</td>
<td>3</td>
<td>11 yr</td>
<td>F</td>
<td>BA</td>
<td>1 yr</td>
<td>1 yr</td>
<td>0.02</td>
<td>9</td>
<td>508</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>10 yr</td>
<td>M</td>
<td>BA</td>
<td>1 yr</td>
<td>1 yr</td>
<td>1.86</td>
<td>134</td>
<td>446</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>7 yr</td>
<td>M</td>
<td>BA</td>
<td>1 yr (F 0)</td>
<td>1 yr</td>
<td>0.47</td>
<td>1</td>
<td>332</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>6 yr</td>
<td>F</td>
<td>BA</td>
<td>1 yr (F 0)</td>
<td>1 yr</td>
<td>0.03</td>
<td>9</td>
<td>508</td>
<td>12</td>
</tr>
</tbody>
</table>

**DISCUSSION**

Immune tolerance is the ultimate goal of transplantation, and many transplant patients have been reported to have ceased immunosuppressant medication for a long period while maintaining a favorable clinical course in clinical practice[6,7]. However, hepatic fibrosis has been reported to have developed in transplant patients who have ceased immunosuppressant medication[21], and there are some concerns over whether the cessation of immunosuppressive treatment leads to fibrosis. We performed a histological analysis in patients who had ceased immunosuppressant medication and examined the impact of the cessation on the liver graft.

As shown by the findings of this and previous studies, the expression of α-SMA increases with the progression of hepatic fibrosis because liver injury that is caused by hepatic viruses or medication activates the fibrosis process, which is higher in the F0-1 stages than in the F4 stage (Figure 1B).

The α-SMA-positive area continued to increase over time in the pediatric patients with tolerance. Pediatric Case 1 showed F0 fibrosis in the liver at all time points, whereas pediatric Case 2 showed a slight progression of fibrosis (F1) eight years after the cessation of the immunosuppressant treatment (Figure 2). However, there were no significant increases in the α-SMA-positive area in the pediatric cases without tolerance (Figure 3).
fully to ensure that the progression of fibrosis is not missed. Because this study was a retrospective analysis and the time of biopsy varied for the individual patients, periodic follow-up examination will be required to evaluate and support this hypothesis. These findings suggest that a routine protocol biopsy could be an important tool to understand the dynamic state of $\alpha$-SMA in detail.

These assumptions suggest that the possibility of developing fibrosis is higher in tolerant patients than in patients who continue immunosuppression, because $\alpha$-SMA expression was consistently high in the tolerant patients in this study. In addition, the expression of $\alpha$-SMA gradually increased in the tolerant patients, indicating that care should be taken in future follow-ups for these patients to ensure that their liver function does not deteriorate.

The liver is known to be the organ most susceptible to immune tolerance compared with other organs, and phenomena in different animal species have been observed that demonstrate that the major histocompatibility complex was successfully engrafted without immunosuppressant medication after an allogeneic liver transplantation.

Figure 1 Changes in alpha smooth muscle actin expression in adult patients with fibrosis. A: The $\alpha$-smooth muscle actin (SMA)-positive area continued to increase over time in all the patients, even when they were in the pre-fibrotic stage (arrow head); B: The $\alpha$-SMA positive area ratio in the patients with fibrosis was calculated based on the fibrosis stage. The $\alpha$-SMA area ratio was higher in the patients with F0-1 fibrosis than in those with F4 fibrosis; C: The photograph on the left shows the $\alpha$-SMA staining in a representative case with F4 fibrosis. The photograph on the right shows a WinRoof digital image, with green corresponding to the area of $\alpha$-SMA-positive staining. $\alpha$-SMA: Alpha smooth muscle actin; LDLT: Living donor liver transplantation.
Figure 2  Change in alpha smooth muscle actin expression in the two pediatric cases with immune tolerance. A: The α-SMA-positive area continued to increase over time in both cases. Case 1 showed F0 fibrosis in the liver at all time points, whereas Case 2 showed a slight progression of fibrosis (F1) eight years after the cessation of immunosuppressive treatment; B: The findings of Azan-Mallory staining and the α-SMA-positive area determined by immunohistochemical analysis are shown. α-SMA: Alpha smooth muscle actin; IS: Immunosuppression.
The effects of immunosuppressive factors produced in the liver and the correlations among antigen-presenting cells in the transplanted liver, including Kupffer cells, sinusoidal endothelial cells, and recipient-derived T cells, are believed to be involved in this immune tolerance. In addition, there have been some studies in mice showing that T cells became unresponsive to the antigen presented from sinusoidal endothelial cells of the specific donor type. A treatment strategy leading to the acquisition of immune tolerance is considered to be important for human liver transplantation to prevent damage to hepatic sinusoidal endothelial cells.

CD68 (KCs) and CD79α (T cells) were immunostained to search for factors related to fibrosis in patients with and without immune tolerance, but there were no significant differences in either KCs or T cells. The major factor determining the progression of fibrosis in patients with immune tolerance still remains unknown, and predictors for the development of tolerance are also unknown. Therefore, we confirm that liver fibrosis staging assessed by biopsy is the main parameter influencing the treatment course.

A previous study indicated that calcineurin inhibitors (CNIs) may inhibit the activity of HSCs and the progression of fibrosis, but convincing evidence has not yet been provided. However, there is a good possibility that the cessation of immunosuppressant medication may cause a certain degree of rejection without abnormal hepatic function or histological rejection. There were also no differences in α-SMA expression between hepatitis C virus-infected patients with and without liver transplants. In addition, CNIs administration may not always inhibit α-SMA expression if there is an infectious background. In addition, the infiltration of inflammatory cells stimulates the expression of pre-fibrotic growth factors, and inflammatory cells and activated HSCs are actually mixed in patients with chronic hepatic dysfunction. Therefore, controlling inflammation is considered to inhibit the progression of fibrosis regardless of the use of immunosuppressant medication.

When deciding whether to resume immunosuppressant medication, it is important to determining whether the progression of fibrosis is due to an antigen response. However, the factors associated with an increase in α-SMA were not determined in the present study in the two pediatric patients, who had most likely acquired immune tolerance. Immunosuppressant medication has not been resumed in these two pediatric patients because they have not shown clear abnormalities in liver function. However, we are performing a strict follow-up regime for both patients to determine whether they will continue to have a good long-term prognosis.

**COMMENTS**

**Case characteristics**
An 18-year-old male with a history of living donor liver transplantation (LDLT) for biliary atresia with no symptoms and an 11-year-old female with a history of LDLT for BA with no symptoms.

**Clinical diagnosis**
Immune tolerant state for a long period of time post-LDLT.

**Differential diagnosis**
Progression of liver fibrosis.

**Laboratory diagnosis**
The result of the liver function and all other tests were within normal limits.

**Imaging diagnosis**
In the imaging examinations, morbid findings were not detected.

**Pathological diagnosis**
In one patient, slight liver fibrosis was revealed by liver biopsy 9 years after the cessation of immunosuppressive therapy.

**Experiences and lesson**
This case report suggested that alpha smooth muscle actin may be a predictor of liver fibrosis; however, this assumption needs further validation from additional cases.

**Figure 3** Changes in alpha smooth muscle actin expression in the four pediatric cases that continued immunosuppression. There was no clear increase in the α-SMA-positive area. α-SMA: Alpha smooth muscle actin; LDLT: Living donor liver transplantation.
REFERENCEs


Hirabaru M et al. Expression of α-SMA in LDLT recipients

atical tolerance by porcine liver allografts. *Nature* 1969; **223**: 472-476 [PMID: 4894426 DOI: 10.1038/223472a0]


32 Marra F. Chemokines in liver inflammation and fibrosis. *Front Biosci* 2002; **7**: d1899-d1914 [PMID: 12161342]


P- Reviewers: Boucek C, Pompili M S- Editor: Ma YJ L- Editor: A E- Editor: Ma S